Skvamps Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.10 M
- Company Age 6 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 86.85%
- Profit Growth 257.98%
- Ebitda 277.23%
- Net Worth 393.69%
- Total Assets 36.98%
About Skvamps Pharma
Skvamps Pharma Private Limited (SPPL) is a Private Limited Indian Non-Government Company incorporated in India on 20 March 2018 (Six years and ten months 16 days old ). Its registered office is in Dharwad, Karnataka, India.
The Company is engaged in the Trading Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Venkatesh Chintamani, Pradeepkumar Choukimath, Nagaraj Maruthi, and Three other members serve as directors at the Company.
Company Details
-
Location
Dharwad, Karnataka, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U51909KA2018PTC111429
-
Company No.
111429
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
20 Mar 2018
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Bangalore
Industry
Who are the key members and board of directors at Skvamps Pharma?
Board Members (6)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Venkatesh Chintamani
|
Director | 20-Mar-2018 | Current |
|
Pradeepkumar Choukimath
|
Director | 20-Mar-2018 | Current |
|
Nagaraj Maruthi
|
Director | 20-Mar-2018 | Current |
|
Suresh Kumbar
|
Director | 20-Mar-2018 | Current |
|
Shivarudra Dharpur
|
Director | 20-Mar-2018 | Current |
|
Krishna Lakshamma
|
Director | 20-Mar-2018 | Current |
Financial Performance of Skvamps Pharma.
Skvamps Pharma Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 86.85% increase. The company also saw a substantial improvement in profitability, with a 257.98% increase in profit. The company's net worth Soared by an impressive increase of 393.69%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Skvamps Pharma?
Unlock access to Skvamps Pharma's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Skvamps Pharma?
Unlock and access historical data on people associated with Skvamps Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Skvamps Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Skvamps Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.